Serum IL-8, IL-10 Levels As Diagnostic And Prognostic Factors In Advanced Non-small Cell Lung Cancer Patients

Sludy objcctive: *fO investigate tl1e progl1ostic signiIicance of il1terleukin(lL)-8illtcl.leukin (lL)-l0 serum levels il1 adval1ced non-sma1l ce1l lul1g cancer (NSCLC)l,atie11ts. I)esign: IL-8. lL-I0 serul11 levels were measured betbre chemotherapy, onct)lllpletiol1 of therapy, by means of a con1mercially availabIe enzyn1e-linkedillllllulloassay. 1'he results were the11 al1alyzed il1 con1parisol1 witll other progl1osticvariables, Setting: University hospital. Patients: Filly-1bur consecutive patients with'I'NM stage lIl or IV NSCLC ul1dergoil1g conventional pIatinum-based regimens.Rcsults: Elevated levels of seruln l1.-8 \ ll-~l0 were fOulld in cancer patients withrespect to healthy control subjects (lL-8 l60.5l I l2.62VS64.97 I2.25; lL-l0 l92.371 l 3.46VS84. l8 f2. l7, respectiveIy; p < ().0l ), witl1 patients with metastatic diseasesllowillg signiIica11tly l1igher levels tl1al1 patients witl1 tIndisseminated cancer (lL-823 l. l 4 1 28.6l VS l l2. l 7 I 4.87,lL- l0 268.27 I 25.03VS l51. l6 f l0.20 respectively; p< 0.0l). Following completion of treatment, patients were classitied as respol1ders iftllcy had achieved either one of the ti)II()wil1g' complete response, partial response, orst[tble disease; al1d 11o11responders, in case of progressive disease. Retrospective analysis()I' [3asal l[.-8 lL-l0 serul11 levels il1 tl1ese two subgroups showed a significant differencebetween responders and l1onresponders (II.-8 l l2.93 f l l .47VS126.38 i l0.88; IL-l01 29.96 i l4.22VS l62. l3 1 l l .69 respectiveIy; p >0.05). Moreover, a flirther significanttlccl.ease il1 lL-8 lL-l0 serul11 levels was observed in nol1responders at the el1d oft1lerapy (IL-8 l35.30 1 l3.46VS l26.38 f l0.88, lL-l0 l75.54 1 l3.60VS162. l3 1 l l .69,l'recl1el11otI1erapy and postcl1elnotl1erapy. respectively; p > 0.05), wl1ereas values inrespollders were fbund to I1ave sigllilical1tIy decreased (IL-8 l 8l .87 I I 9.42VS l l2.93 I514.46; IL-10 208.18+ 20.05VSI29.96+ 14.22, prechemotherapy and postchemotherapy, respectively; p < 0.05). Conclusions: In conclusion, this study shows that the measurement of pretreatment IL^ IL-10 serum levels is a reliable, sensitive and ease method and is of independent prognostic utility in patients with NSCLC and may be useful for detection of disease progression.